Last edition
News about "David Weinreich"
Merck Wins US FDA Breakthrough Therapy Designation Status for Enpatoran in Lupus
Merck has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for enpatoran in lupus patients with active skin manifestations, advancing a potential first approved treatment for cutaneous lupus.
David Weinreich | 09/07/2026 | By News Bureau
Merck Partners with Versant Ventures to Launch Saturnus Bio
Merck has partnered with Versant Ventures to establish Saturnus Bio, advancing precision medicine through gene modulation technologies for rare genetic cardiomyopathies.
David Weinreich | 25/06/2026 | By News Bureau
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
David Weinreich | 22/05/2026 | By News Bureau | 153
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy